Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "non-Cognitive" Outcomes of Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 52, Issue 3, 2016, Pages 1055-1064

  Ingber, Adam P ^a   Hassenstab, Jason ^b   Fagan, Anne M ^b   Benzinger, Tammie L S ^b   Grant, Elizabeth A ^b   Holtzman, David M ^b   Morris, John C ^b   Roe, Catherine M ^b  

^a Program on Infrastructure Policy   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; biomarkers; cognitive reserve; dementia

Indexed keywords

BIOLOGICAL MARKER; AMYLOID BETA PROTEIN; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; COGNITION ASSESSMENT; COGNITIVE RESERVE; FEMALE; FOLLOW UP; FUNCTIONAL ACTIVITIES QUESTIONNAIRE; GERIATRIC DEPRESSION SCALE; HUMAN; IMAGE PROCESSING; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEUROLOGIC DISEASE ASSESSMENT; NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; AGED; BRAIN; COHORT ANALYSIS; DEPRESSION; DIAGNOSTIC IMAGING; GERIATRIC ASSESSMENT; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; COGNITIVE RESERVE; COHORT STUDIES; DEPRESSION; FEMALE; GERIATRIC ASSESSMENT; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SURVEYS AND QUESTIONNAIRES; TAU PROTEINS;

EID: 84971571197     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150478     Document Type: Article

References (42)

1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, Network DIA (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804
2. Morris JC (2005) Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord 19, 163-165
3. Benzinger TLS, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, others (2013) Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A 110, E4502-E4509
4. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM, Dominantly Inherited Alzheimer Network (2014) Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 6, 226ra30
5. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292
6. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A (1988) Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 23, 138-144
7. Stern Y (2002) What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 8, 448-460
8. Mortimer JA (1997) Brain reserve and the clinical expression of Alzheimer's disease. Geriatrics 52(Suppl 2), S50-S53
9. Scarmeas N, Zarahn E, Anderson KE, Habeck CG, Hilton J, Flynn J, Marder KS, Bell KL, Sackeim HA, Van Heertum RL, Moeller JR, SternY(2003) Association of life activities with cerebral blood flow in Alzheimer disease: Implications for the cognitive reserve hypothesis. Arch Neurol 60, 359-365
10. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144
11. Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24, 87-97
12. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613
13. Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1, 213-225
14. Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652-656
15. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T (2009) Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389
16. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/betaamyloid( 42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343-349
17. Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC (2011) Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 76, 501-510
18. Zekry D, Graf CE, Giannelli SV, Gold G, Michel JP (2012) Non-cognitive outcomes in trials of disease-modifying drugs for Alzheimer's disease. Eur Geriatr Med 3, 37-42
19. Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, Aisen P, Cummings J, Raskin J, MohsR(2014) Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. J Alzheimers Dis 43, 949-955
20. Zahodne LB, Manly JJ, MacKay-Brandt A, Stern Y (2013) Cognitive declines precede and predict functional declines in aging and Alzheimer's disease. PLoS One 8, e73645
21. Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, Tremont G, Initiative ADN (2010) Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: Normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol 67, 688-696
22. Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC (2013) CSF biomarkers of Alzheimer disease: "Noncognitive" outcomes. Neurology 81, 2028-2031
23. Berg L, McKeel DW, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55, 326-335
24. Villareal DT, Grant E, Miller JP, Storandt M, McKeel DW, Morris JC (2003) Clinical outcomes of possible versus probable Alzheimer's disease. Neurology 61, 661-667
25. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566-572
26. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414
27. FolsteinMF, Folstein SE, McHugh PR (2014) "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198
28. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S (1982) Measurement of functional activities in older adults in the community. J Gerontol 37, 323-329
29. Manly JJ, Schupf N, Tang MX, Stern Y (2005) Cognitive decline and literacy among ethnically diverse elders. J Geriatr Psychiatry Neurol 18, 213-217
30. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314
31. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12, 233-239
32. Sheikh JI, Yesavage JA (1986) Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. In Clinical Gerontology: A Guide to Assessment and Intervention. The Haworth Press, NY
33. Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, Snyder AZ (2004) A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: Reliability and validation against manual measurement of total intracranial volume. Neuroimage 23, 724-738
34. Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL (2005) Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology 64, 1032-1039
35. Head D, Snyder AZ, Girton LE, Morris JC, Buckner RL (2005) Frontal-hippocampal double dissociation between normal aging and Alzheimer's disease. Cereb Cortex 15, 732-739
36. Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968-980
37. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM (2002) Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341-355
38. Fischl B, Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D, Caviness V, Makris N, Rosen B, Dale AM (2004) Automatically parcellating the human cerebral cortex. Cereb Cortex 14, 11-22
39. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519
40. Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM (2011) Visininlike protein-1: Diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 70, 274-285
41. Bates DM (2010) lme4: Mixed-effects modeling with R. URL http://lme4.r-forge.r-project.org/lMMwR/lrgprt.pdf
42. Razlighi QR, Stallard E, Brandt J, Blacker D, Albert M, Scarmeas N, Kinosian B, Yashin AI, Stern Y (2014) A new algorithm for predicting time to disease endpoints in Alzheimer's disease patients. J Alzheimers Dis 38, 661-668